FindTrial
Sign In

Adjuvant endocrine therapy

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, Dana-Farber Cancer Institute

Conditions

Breast CancerHER2-positive Breast CancerHormone Receptor Positive Breast CancerInvasive Carcinoma of the BreastMicrometastasis Breast CancerNode Negative Breast Cancer

Phase 2

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
CompletedNCT03078751
Novartis PharmaceuticalsBreast Cancer
Start: 2017-06-20End: 2020-03-09Updated: 2021-10-11
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Active, not recruitingNCT04569747
Dana-Farber Cancer InstituteBreast Cancer, HER2-positive Breast Cancer, Hormone Receptor Positive Breast Cancer +3
Start: 2021-01-11End: 2030-09-01Updated: 2026-04-02

Phase 3

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
WithdrawnNCT03081234
Novartis PharmaceuticalsBreast Cancer
Start: 2018-03-31End: 2025-11-17Updated: 2018-03-15

Related Papers

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).
UNC Libraries2024-10-09
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)
JCO Oncology Practice2024-07-1910 citations
Abstract PO4-12-11: Patient (pt) time burden with IV vs subcutaneous (SC) administration of trastuzumab/pertuzumab (HP): A time and motion (T+M) substudy of a single arm phase II trial of adjuvant endocrine therapy plus HP for stage I HER2+ breast cancer
Cancer Research2024-05-02
Abstract OT3-05-06: EarLEE-2: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), intermediate-risk, early breast cancer (EBC)
Cancer Research2018-02-152 citations